28
Table 6.4.3 Success Measures
Item
Zenith Standard Risk
Surgical Standard Risk
Zenith High Risk
Zenith Roll-in
Technical success
1
99.5%
(199/200)
98.8%
(79/80)
100%
(100/100)
100%
(52/52)
Procedural success at 30 days
2
95.1%
(155/163)
88%
(60/68)
86%
(70/81)
91%
(30/33)
Treatment success at
12 months
3
89%
(122/137)
85%
(52/61)
70%
(44/63)
87%
(26/30)
1
Patent graft following deployment.
2
Technical success with no major complications, patent graft and no Type I or Type III endoleaks at 30 days.
3
Procedural success extended to 12 months with no aneurysm enlargement (>5 mm).
Figure 6.4.3 presents freedom from morbidity (events in the morbidity index) to 12 months. The accompanying table presents the Kaplan-Meier analysis at 1,
6 and 12 months.
Figure 6.4.3 Freedom from Morbidity (0-365 days)
Zenith Standard Risk
(N=200, 38 patients with events to 30 days
43 patients with events to 6 months
45 patients with events to 12 months)
Surgical Standard Risk
(N=80, 34 patients with events to 30 days
38 patients with events to 6 months
41 patients with events to 12 months)
Per
cen
t F
reedom fr
om Morbidit
y
Months After Procedure
1 month
6 months
12 months
n
%
n
%
n
%
Zenith standard risk
162
81.0
154
78.5
133
77.4
Surgical standard risk
45
57.1
39
52.0
33
47.8
n= Patients alive and free of morbidity at the end of the interval
P
= <.001
Tables 6.4.4 through 6.4.7 describe results of the Zenith AAA Endovascular Graft subjects as reported by the Core Lab. Device performance factors analyzed
by the Core Lab include device integrity (Table 6.4.4), device patency (Table 6.4.5), migration (Table 6.4.6) and limb separation (Table 6.4.7).
Table 6.4.4 Abdominal Radiographic Findings – Device Integrity
Item
Zenith Standard Risk
Zenith High Risk
Zenith Roll-in
Stent Fractures
1
Pre-discharge
0.0%
(0/172)
0.0%
(0/81)
0.0%
(0/39)
30 day
0.0%
(0/172)
0.0%
(0/83)
0.0%
(0/43)
6 month
0.0%
(0/166)
0.0%
(0/78)
0.0%
(0/35)
12 month
0.0%
(0/148)
0.0%
(0/60)
0.0%
(0/28)
24 month
0.0%
(0/93)
0.0%
(0/42)
0.0%
(0/19)
Barb Separation
2
Pre-discharge
0.0%
(0/176)
0.0%
(0/86)
0.0%
(0/39)
30 day
0.0%
(0/178)
0.0%
(0/86)
0.0%
(0/43)
6 month
1.2%
(2/167)
2.5%
(2/80)
0.0%
(0/35)
12 month
2.0%
(3/149)
1.7%
(1/60)
0.0%
(0/28)
24 month
1.1%
(1/93)
0.0%
(0/42)
0.0%
(0/19)
Graft material rupture
Pre-discharge
0.0%
(0/176)
0.0%
(0/86)
0.0%
(0/39)
30 day
0.0%
(0/178)
0.0%
(0/86)
0.0%
(0/43)
6 month
0.0%
(0/167)
0.0%
(0/80)
0.0%
(0/35)
12 month
0.0%
(0/149)
0.0%
(0/60)
0.0%
(0/28)
24 month
0.0%
(0/93)
0.0%
(0/42)
0.0%
(0/19)
1
Stent fracture percentages are for main body. There were also no right iliac leg, left iliac leg, occluder, converter, left iliac extension, right iliac extension or main body extension
fractures observed by the Core Lab.
2
Patients with separation of 1 or 2 barbs (of 10 or 12 total); no adverse clinical sequelae.
Table 6.4.5 CT Findings – Graft Patency
Item
Zenith Standard Risk
Zenith High Risk
Zenith Roll-in
Graft patency
30 day
100%
(185/185)
99%
(85/86)
100%
(47/47)
6 month
99%
(183/184)
100%
(74/74)
100%
(39/39)
12 month
99%
(153/155)
100%
(62/62)
100%
(30/30)
24 month
100%
(96/96)
100%
(33/33)
100%
(25/25)
Table 6.4.6 CT Findings – Graft (Main Body) Migration
Item
Zenith Standard Risk
Zenith High Risk
Zenith Roll-in
Graft migration (>5 mm) at 12 months
with clinical sequelae
1
or intervention
0.0%
(0/162)
0.0%
(0/71)
0.0%
(0/34)
without clinical sequelae
1
or intervention
2.5%
(4/162)
2.8%
(2/71)
0.0%
(0/34)
Graft migration (>10 mm)
0.0%
(0/162)
0.0%
(0/71)
0.0%
(0/34)
1
Migration with clinical sequelae would include endoleak, conversion, rupture or AAA-related death.